![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Lilly Wins European Approval for Anti-Migraine Drug
Lilly Wins European Approval for Anti-Migraine Drug
![Eli lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Lilly_Logo.jpg?t=1616695880&width=430)
November 30, 2018
The European Medicines Agency approved Eli Lilly’s anti-migraine drug Emgality (galcanezumab) as a treatment for patients who have at least four migraine days per month.
The drug works by blocking the release of calcitonin gene-related peptide (CGRP). The FDA approved Emgality in September.
Amgen’s Aimovig (erenumab) and Teva’s Ajovy (fremanezumab) were previously approved as treatments for migraine.
Upcoming Events
-
21Oct